203 related articles for article (PubMed ID: 18431823)
1. Merck accused of disguising its role in research.
Cressey D
Nature; 2008 Apr; 452(7189):791. PubMed ID: 18431823
[No Abstract] [Full Text] [Related]
2. Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research.
Berger E
Ann Emerg Med; 2008 Aug; 52(2):137-9. PubMed ID: 18672488
[No Abstract] [Full Text] [Related]
3. Clinical trials and tribulations. Allegations of waste: the 'seeding' study.
Malakoff D
Science; 2008 Oct; 322(5899):213. PubMed ID: 18845743
[No Abstract] [Full Text] [Related]
4. Merck VIOXX "warning" is questioned.
Allen TS; Henderson JH
Tex Med; 2005 May; 101(5):5-6. PubMed ID: 15948521
[No Abstract] [Full Text] [Related]
5. Painkiller verdict shows mistrust of Merck.
Khamsi R
Nature; 2005 Aug; 436(7054):1070. PubMed ID: 16121136
[No Abstract] [Full Text] [Related]
6. Journal grows suspicious of Vioxx data.
Wadman M
Nature; 2005 Dec; 438(7070):899. PubMed ID: 16355178
[No Abstract] [Full Text] [Related]
7. Manipulating a journal article.
N Y Times Web; 2005 Dec; ():WK11. PubMed ID: 16453395
[No Abstract] [Full Text] [Related]
8. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
Armstrong D
Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
[No Abstract] [Full Text] [Related]
9. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
Moynihan R
BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
[No Abstract] [Full Text] [Related]
10. Medical journal criticizes Merck over Vioxx data.
Berenson A
N Y Times Web; 2005 Dec; ():A1, C13. PubMed ID: 16456990
[No Abstract] [Full Text] [Related]
11. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
12. Implications of the rofecoxib trials.
Kozma CM
Manag Care Interface; 2005 Oct; 18(10):61-2. PubMed ID: 16265937
[No Abstract] [Full Text] [Related]
13. Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld.
Couzin J
Science; 2005 Dec; 310(5755):1755. PubMed ID: 16357236
[No Abstract] [Full Text] [Related]
14. Make or break time in Vioxx drama.
Nature; 2006 Mar; 440(7082):277. PubMed ID: 16541045
[No Abstract] [Full Text] [Related]
15. Regulating the market in human research participants.
Lemmens T; Miller PB
PLoS Med; 2006 Aug; 3(8):e330. PubMed ID: 16866575
[TBL] [Abstract][Full Text] [Related]
16. Factor VIIa for ICH: behind the scenes of an academic-industry collaborative trial.
Mayer SA; Davis S; Steiner T; Diringer MN; Broderick J
Int J Stroke; 2007 Aug; 2(3):164-8. PubMed ID: 18705937
[No Abstract] [Full Text] [Related]
17. The preacher who's raising hell with Merck.
Parloff R
Fortune; 2005 Aug; 152(3):20. PubMed ID: 16097189
[No Abstract] [Full Text] [Related]
18. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
Cahana A; Mauron A
J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707
[No Abstract] [Full Text] [Related]
19. Painkiller in the dock.
Nature; 2005 Jul; 436(7050):459. PubMed ID: 16049447
[No Abstract] [Full Text] [Related]
20. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.
Psaty BM; Kronmal RA
JAMA; 2008 Apr; 299(15):1813-7. PubMed ID: 18413875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
